Linked Life Data

2687199

Source:http://linkedlifedata.com/resource/pubmed/id/2687199

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1990-1-25
pubmed:abstractText
Ioversol, the new nonionic, low-osmolality contrast agent, has been well characterized chemically and in terms of basic toxicity testing. Ioversol has a formula similar to that of other nonionic agents, and has been used in a variety of clinical studies. These have been reviewed in detail in other papers. This article reviews the worldwide experience to date with the intra-arterial use of this contrast agent. Ioversol has been given to more than 500 patients for studies including intra-arterial digital subtraction angiography, and cerebral, visceral, peripheral, and cardiac angiography. In 23 carefully monitored studies, ioversol was shown to be safe and diagnostically efficacious, as compared with several high- and low-osmolality agents. To date, there have been no deaths or other severe reactions with this new nonionic formulation. Ioversol is likely to provide a useful addition to the current formulary of low-osmolality agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0020-9996
pubmed:author
pubmed:issnType
Print
pubmed:volume
24 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S61-6
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Clinical experience with ioversol for angiography.
pubmed:affiliation
Department of Radiology, Boston University School of Medicine, Massachusetts.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study